Vicki L. Sato - 02 Jan 2025 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Reporting relationship: Director
Issuer ticker: DNLI
Reported as of: 02 Jan 2025
Net transaction value: -$64,403
SEC form: 4
Accepted by SEC: 03 Jan 2025, 16:13:51 UTC
Prior SEC filing: 12 Nov 2024
Next SEC filing: 08 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Tyler Nielsen, by power of attorney

Key filing fact

Vicki L. Sato filed Form 4 for Denali Therapeutics Inc. (DNLI) on 03 Jan 2025.

Key facts

This page summarizes Vicki L. Sato's Form 4 filing for Denali Therapeutics Inc. (DNLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jan 2025, 16:13.

Change

Previous filing in this sequence was filed on 12 Nov 2024.
Current net transaction value: -$64,403.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNLI transaction

Common Stock

Sale

Transaction value: $64,403
Shares: -3,080
Change %: -2.8%
Price: $20.91
Shares after: 107,976
Date: 02 Jan 2025
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024.

Footnote F2

The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.75 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

Includes 5,967 unvested RSUs.